Key result
Genetic polymorphisms of CYP2C9 and RAAS genes determine significant interindividual variability in the pharmacokinetic and pharmacodynamic responses to angiotensin II receptor blockers.
Why the study?
Genetic polymorphisms of CYP2C9 and RAAS genes influence ARB pharmacokinetics and pharmacodynamics, determining substantial interindividual variability in treatment response.
Do genetic polymorphisms of CYP2C9 and RAAS genes affect the pharmacokinetics and pharmacodynamics of angiotensin II receptor blockers?
Do genetic polymorphisms of CYP2C9 and RAAS genes affect the pharmacokinetics and pharmacodynamics of angiotensin II receptor blockers?
Pharmacogenetic testing for CYP2C9 and RAAS polymorphisms may help predict individual responses to specific ARBs, facilitating a personalized approach to antihypertensive therapy.
This scientific review presents a current data on the effect of genetic polymorphism of CYP2C9 genes and genes encoding components of the renin-angiotensin-aldosterone system (RAAS) on the angiotensin II receptor blockers (ARBs) pharmacokinetics and pharmacodynamics. The data shows that genetic polymorphisms of these genes determine the large interindividual variability of the pharmacological response to ARBs. In this article, we carried out a comprehensive review of recent findings on interpatient variability in antihypertensive therapy response due to genetic factors and individualized treatment approach in ARBs therapy.
No takes yet. Share an insight, caveat, or question.
Sinitsina et al. (2020) conducted a review in Arterial hypertension. Angiotensin II receptor blockers (ARBs) and genetic polymorphisms (CYP2C9, RAAS) was evaluated. Genetic polymorphisms of CYP2C9 and RAAS genes determine significant interindividual variability in the pharmacokinetic and pharmacodynamic responses to angiotensin II receptor blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: